Otsuka Pharmaceutical Company, Limited

Kunio Oshima

Nobuaki Ito

Hiroshi Yamashita

Shin Miyamura

Tatsuyoshi Tanaka

Hideaki Kuroda

Satoshi Shimizu

Haruka Takahashi

Jun Matsubara

Shinichi Taira

Takumi Sumida

Hironobu Ishiyama

Takeshi Kuroda

Tae Fukushima

Hokuto Yamabe

Shuuji Matsumura

Tomoichi Shinohara

Kuninori Tai

Yasuhiro Menjo

Isao Takemura

Masatoshi Chihiro

Takahiro Tomoyasu

Yasuo Koga

Takahito Yamauchi

Kazuhide Ohta

Hideki Kitagaki

Junpei Haruta

Masataka Ueda

Hidetaka Hiyama

Kenji Watanabe

Yoko Sakamoto

Hitoshi Nagao

Takashi Oshiyama

Toshiyuki Onogawa

Kenji Tsujimae

Hideki Kawasome

Kazuhiko Fujita

Chiharu Kitajima

Masaaki Takano

Sunao Nakayama

Kazumi Kondo

Yasuo Oshiro

Yohji Sakurai

Noriaki Takemura

Motohiro Itotani

Naohiro Isono

Tsuyoshi Nagase

The present invention provides a heterocyclic compound represented by the general formula (1): The compound of the present invention has a wide treatment spectrum for mental disorders including central nervous system disorders, no side effects and high safety.

Piperazine-substituted benzothiophenes for treatment of mental disorders

The present invention provides a heterocyclic compound represented by the general formula (1): The compound of the present invention has a wide treatment spectrum for mental disorders including central nervous system disorders, no side effects and high safety. 

The present invention provides a novel diazepine compound that blocks the Icurrent or the Kv1.5 channel potently and more selectively than other Kchannels. The present invention relates to a diazepine compound represented by General Formula (1)  

Nitrogen-containing compounds and pharmaceutical compositions thereof for the treatment of atrial fibrillation

The present invention provides a novel benzodiazepine compound that blocks the Icurrent or the Kv1.5 channel potently and more selectively than other Kchannels. The benzodiazepine compound of the invention is represented by General Formula (1) wherein R, R, R, and Rare each independently hydrogen or lower alkyl; Rand Rmay be linked to form lower alkylene; wherein Rand Rare each independently hydrogen or organic group;

Benzodiazepine compound and pharmaceutical composition

Thiazole compounds for inhibiting the activity of phosphodiesterase 4, the production of tumor necrosis factor alpha, and the production of interleukin 4. The compounds of the invention are represented by general formula (1): 

Thiazole compounds and their use for inhibiting phosphodiesterase 4, TNF-&#x3b1;, and IL-4

The present invention provides a carbostyril compound represented by General Formula (1) or a salt thereof, wherein A is a direct bond, a lower alkylene group, or a lower alkylidene group; X is an oxygen atom or a sulfur atom; Rand Reach represent a hydrogen atom; the bond between the 3 and 4 positions of the carbostyril skeleton is a single bond or a double bond; Ris a hydrogen atom, etc; Ris a hydrogen atom, etc; and Ris a hydrogen atom, etc. The carbostyril compound or salt thereof of the present invention induces the production of TFF, and thus is usable for the treatment and/or prevention of disorders such as alimentary tract diseases, oral diseases, upper respiratory tract diseases, respiratory tract diseases, eye diseases, cancers, and wounds.

Carbostyril compound

The present invention provides a novel benzodiazepine compound that blocks the Icurrent or the Kv1.5 channel potently and more selectively than other Kchannels. The benzodiazepine compound of the invention is represented by General Formula (1)  

A heterocyclic compound or a salt thereof represented by the formula (1): where Rrepresents a hydrogen atom or a lower alkyl group; A represents a lower alkylene group or lower alkenylene group; and Rrepresents an aromatic group or a heterocyclic group. The compound of the present invention has a wide treatment spectrum for mental disorders including central nervous system disorders, no side effects and high safety. 

Derivatives of 4-piperazin-1-yl-4-benzo[B]thiophene suitable for the treatment of CNS disorders

Thiazole compounds for inhibiting the activity of phosphodiesterase 4, the production of tumor necrosis factor alpha, and the production of interleukin 4. The compounds of the invention are represented by general formula (1): wherein A is any one of the following groups (i) and (ii): (i) &#x2014;CO&#x2014;B&#x2014; wherein B is a Calkylene group and (ii) &#x2014;CO&#x2014;Ba&#x2014; wherein Ba is a Calkenylene group, and include optical isomers and salts of the compounds.

Thiazole compound and use thereof

Growing community of inventors

Tokushima, Japan

Kunio Oshima